The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...

SAN FRANCISCO, March 03, 2020 -- UNITY Biotechnology, Inc. (UNITY) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.

As of late, it has definitely been a great time to be an investor Unity Biotechnology

UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the first patient has been dosed in a Phase 2 study of UBX0101 in patients with osteoarthritis (OA) of the knee. “In June, we announced promising results from our Phase 1 study of UBX0101 in patients with OA of the knee showing that our senolytic molecule was well tolerated and had a dose-dependent improvement in pain and function across multiple clinical endpoints,” said Jamie Dananberg, chief medical officer of UNITY. The Phase 2 study of UBX0101 in patients with painful, moderate-to-severe OA of the knee is expected to enroll approximately 180 patients.

SOUTH SAN FRANCISCO, Calif., March 11, 2020 -- UNITY Biotechnology, Inc. (UNITY) , a biotechnology company developing therapeutics to extend healthspan by slowing,.

UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today provided pipeline and business updates. In October 2019 UNITY announced that the first patient had been dosed in a Phase 2 study of UBX0101, an inhibitor of the MDM2/p53 protein-protein interaction, in patients with moderate-to-severe osteoarthritis (OA) of the knee.

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

The following are seven top fintech startups in the Philippines which made significant strides last year and are now poised for recognition.

It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]

UNITY Biotechnology today announced the appointment of Anirvan Ghosh, Ph.D., as CEO and member of the Board of Directors, effective March 30, 2020. Dr. Ghosh joins UNITY from Biogen, where he served as Senior Vice President, Head of Research and Early Development. Current UNITY CEO, Keith Leonard, will be leaving his operating role due to personal circumstances, but will continue as Chairman of the Board of Directors.

Unity Biotechnology has 3 potential catalysts coming in 2H 2020.The longevity space is getting an increasingly large amount of attention which should only grow with clinical success.Unity Biotechnology’s current share price presents a good risk/reward because…

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) * Forty Seven Inc (NASDAQ: FTSV)( announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD)) * IGM Biosciences Inc (NASDAQ: IGMS) * Iovance Biotherapeutics Inc (NASDAQ: IOVA) * Karyopharm Therapeutics Inc (NASDAQ: KPTI)(announced positive late-stage results for selinexor) * Passage Bio Inc (NASDAQ: PASG)(IPOed Friday) * Syneos Health Inc (NASDAQ: SYNH) * Trillium Therapeutics Inc (NASDAQ: TRIL)(moved in sympathy with Forty Seven, as it has a similar drug in the pipeline for solid tumor) * Zynex Inc. (NASDAQ: ZYXI)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 2) * Aerie Pharmaceuticals Inc (NASDAQ: AERI) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Akorn, Inc. (NASDAQ: AKRX) * ANI Pharmaceuticals Inc (NASDAQ: ANIP)(moved lower despite FDA nod for a generic version of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Alzheimer's related dementia drug) * Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) * Axovant Gene Therapies Ltd (NASDAQ: AXGT) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * Eagle Pharmaceuticals Inc (NASDAQ: EGRX) (reacted to its fourth-quarter results) * Evolus Inc (NASDAQ: EOLS) * EXACT Sciences Corporation (NASDAQ: EXAS) * GenMark Diagnostics, Inc (NASDAQ: GNMK) * Imv Inc (NASDAQ: IMV) * Neurometrix Inc (NASDAQ: NURO) * Portola Pharmaceuticals Inc (NASDAQ: PTLA) * Precigen Inc (NASDAQ: PGEN) * Taro Pharmaceutical Industries Ltd. (NYSE: TARO) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TherapeuticsMD Inc (NASDAQ: TXMD) * Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) * Viking Therapeutics Inc (NASDAQ: VKTX)Related Link: How The COVID-19 Outbreak Is Benefiting Biotech InvestorsStocks In Focus GenMark Starts Shipping COVID-19 Test Kits GenMark said it has begun shipping ePlex Research Use Only, or RUO, test kits to detect COVID-19 virus. The initial shipment will go to its Hong Kong distributor as well as several U.S. customers having access to clinical samples.Separately, the company reported fourth-quarter results, showing 24% year-over-year revenue growth and a narrower loss of 17 cents per share, while analysts estimated a loss of 16 cents per share.The stock jumped 21.65% to $4.27 in after-hours trading.Novartis' Sandoz Unit Agrees For $195M Settlement In Generics Price Fixing Probe Novartis AG's (NYSE: NVS) Sandoz unit said it has reached a resolution with the U.S. DoJ in a 3-year-long antitrust investigation carried out by the agency into the U.S. generic drug industry. Sandoz said the settlement pertains to instances of misconduct by the company between 2013 and 2015 with certain generic drugs sold in the U.S. As part of the agreement, Sandoz will pay $195 million.Unity Biotech Taps Former Biogen Executive as CEO Unity Biotechnology Inc (NASDAQ: UBX) announced the appointment of Anirvan Ghosh as CEO and member of the board, effective March 30. Ghosh was previously with as Biogen Inc (NASDAQ: BIIB) as SVP, Head of Research and Early Development.The company said current CEO Keith Leonard will step down from the role due to personal circumstances.KemPharm Filed Regulatory Application For ADHD Drug KemPharm Inc (NASDAQ: KMPH) said it has submitted a NDA for KP415, its investigational asset to treat attention deficit hyperactivity disorder, or ADHD. KP415 contains serdexmethylphenidate and KemPharm's prodrug d-methylphenidate.The stock jumped 37.61% to 45 cents in after-hours trading.CanFite Submits Safety Report Showing Favorable Safety Snd Risk-Benefit Ratios CAN FITE BIOPHARMA ADR REP 30 ORD (NYSE: CANF) announced submission of annual Drug Safety Update Reports to health regulatory agencies concerning Piclidenoson and Namodenoson, which show both investigational-stage drugs have favorable safety profiles and risk-benefit ratios in more than 1,500 patients.In premarket trading Tuesday, the shares were surging up 29.92% to $1.65.Thermo Fisher To Buy Qiagen For $10B In Cash Thermo Fisher Scientific Inc. (NYSE: TMO) announced a deal to buy molecular diagnostics company Qiagen NV (NYSE: QGEN) for 39 euros per share in cash or 9 billion euros ($10 billion).In premarket trading Tuesday, Qiagen shares were rallying 16.06% to $41.92 and Thermo Fisher shares were moving up 3.26% to $314.90,Alnylam Says Inherited Liver Enzyme Deficiency Drug Approved In Europe Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) said the European Commission has granted marketing authorization for GIVLAARI, an injection for subcutaneous use targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria in adults and adolescents aged 12 years and olderLily Assuages COVID-19 Concerns Eli Lilly And Co (NYSE: LLY) issued an update alleviating any potential impact from COVID-19, stating that it does not anticipate shortages for any of its products, including all forms of insulin. It also said it does not source any of its approved medicines from China, and that its insulin manufacturing sites in the United States and Europe have not been impacted by coronavirus.View more earnings on IBBIn pre-market trading Tuesday, the shares were adding 0.87% to $134 .Earnings Omeros Corporation's (NASDAQ: OMER) fourth-quarter revenues rose 12% to $33.4 million and the net loss widened from 48 cents per share to 58 cents per share.The stock added 17% to $14.73 in after-hours trading.Zogenix, Inc. (NASDAQ: ZGNX) reported fourth-quarter revenues of $1.95 million compared to no revenues a year ago. The net loss per share widened from 53 cents to $1.26. Analysts estimated a loss of $1.06 per share.The stock slipped 6.93% to $23.50 in after-hours trading.Precigen reported fourth-quarter revenues of $17 million, sharply lower than $41.19 million a year ago. The net loss, however, narrowed from $2.59 per share to $1.09 per share. Analysts expected a loss of 27 cents per share on 23.4 million.The stock declined 7.93% to $3.60 in after-hours trading.Offerings Close on the heels of reporting positive late-stage data for selinexor, Karyopharm announced the commencement of a registered underwritten public offering of $150 million worth of its common shares.The stock moved down 6.17% to $26.01 in after-hours trading.On The Radar Earnings * Antares Pharma Inc (NASDAQ: ATRS) (before the market open) * Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) (before the market open) * Neuronetics Inc (NASDAQ: STIM) (before the market open) * TG Therapeutics Inc common stock (NASDAQ: TGTX) (before the market open) * Sierra Oncology Inc (NASDAQ: SRRA) (before the market open) * Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (after the close) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX) (after the close) * VIVUS, Inc. (NASDAQ: VVUS) (after the close) * Voyager Therapeutics Inc (NASDAQ: VYGR) (after the close) * DURECT Corporation (NASDAQ: DRRX) (after the close) * Cytokinetics, Inc. (NASDAQ: CYTK) (after the close)See more from Benzinga * Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates * The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off * The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Despite the long odds facing a Republican in a Democratic district, the donations come pouring in.

SOUTH SAN FRANCISCO, Calif., May 07, 2020 -- UNITY Biotechnology, Inc. (UNITY) , a biotechnology company developing therapeutics to extend healthspan by slowing,.

As of late, it has definitely been a great time to be an investor in Unity Biotechnology.

SAN FRANCISCO, Oct. 23, 2019 -- UNITY Biotechnology, Inc. (UNITY) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.

SAN FRANCISCO, Nov. 06, 2019 -- UNITY Biotechnology, Inc. (UNITY) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.

UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that two abstracts summarizing recent studies on the role of senolytic medicine in knee osteoarthritis, including a late breaking abstract on the recent Phase 1b study of UBX-0101, have been accepted for presentation at the American College of Rheumatology (ACR) 2019 Annual Meeting being held November 8-13, 2019 in Atlanta, Georgia. UBX0101 is a senolytic small molecule inhibitor of the MDM2/p53 protein interaction.

SAN FRANCISCO, Feb. 24, 2020 -- UNITY Biotechnology, Inc. (“UNITY”) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.

Author summary We report a novel frameshift variant in MYL2 that is associated with a severe form of infantile-onset hypertrophic cardiomyopathy. The impact of the variant is only observed in the recessive form of the disease found in the proband and not in t…

UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced updates related to UBX0101. In February 2020, UNITY announced that it had dosed the first patients with moderate-to-severe osteoarthritis (OA) of the knee in a Phase 1b study to explore the safety, tolerability and initial efficacy of a single 8.0 mg dose or multiple doses (two 4.0 mg doses separated by one month) of UBX0101, an inhibitor of the p53/MDM2 protein-protein interaction. Also in February 2020, UNITY announced completion of enrollment of a Phase 2 study of UBX0101 in patients with moderate-to-severe OA of the knee.

SAN FRANCISCO, May 04, 2020 -- UNITY Biotechnology, Inc. (UNITY) , a biotechnology company developing therapeutics to extend healthspan by slowing, halting or.

UNITY Biotechnology, Inc. today announced that Anirvan Ghosh, Ph.D., has officially joined the company as Chief Executive Officer. As previously announced, Dr. Ghosh is a renowned scientist and drug development leader who joins UNITY from Biogen, where he served as Senior Vice President, Head of Research and Early Development. Former UNITY CEO, Keith Leonard, will continue as Chairman of the Board of Directors.

The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]